Robert W. Baird raised Humana's stock price target to $390 from $205, signaling potential upside despite a 5.87% stock drop on a turbulent market day. Meanwhile, Raymond James downgraded Humana to Market Perform, indicating expected performance in line with the broader market. Humana's management confirmed 2026 financial goals remain on track, aiming for a pretax margin of at least 3.00% by 2028 through Medicare Advantage margin growth and cost reductions. This mixed analyst sentiment reflects cautious optimism about Humana's future amid market volatility.
Humana's stock was upgraded to Outperform by Evercore ISI following strong Q2 2026 results. The company reported adjusted earnings of $7.61 per share and revenues of $40.9 billion, both exceeding analyst expectations, driven by a 20.7% growth in medi...
Humana Inc., a health insurer focused on Medicare Advantage plans, reported a sharp decline in profit margins, with Q2 2026 pre-tax margin at 1.8%, down from 6.7% in 2020. The company targets a sustainable 3% pre-tax margin by 2028 through improving ...
Humana reported second-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $7.61 versus the expected $7.22, and revenue of $40.87 billion beating estimates. The company maintained its 2026 adjusted profit outlook ...
Humana reported a second-quarter net income of $694 million, driven by a surge in Medicare Advantage enrollees to 7.1 million, up from 5.8 million a year ago. Despite rising medical costs industry-wide, Humana managed to keep its benefit ratio at 91....
A securities fraud lawsuit against Humana Inc. and its former CEO and CFO is proceeding after a judge ruled key claims valid. The lawsuit alleges that from July 2022 to October 2024, Humana misled investors about rising healthcare utilization costs, ...
